> ## Content Index
> Fetch the complete content index at: https://financeherald.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# GSK's New Drug Could Spare Rectal Cancer Patients Surgery
- URL: https://financeherald.com/gsks-new-rectal-cancer-approval-could-spare-some-patients-surgery-the-pivotal-data-are-less-stunning-than-the-original-100-trial/
- Published: 2026-10-24T21:48:21.000Z
- Updated: 2026-10-24T21:50:55.000Z
- Description: An FDA approval could let a biomarker-defined subset of rectal cancer patients skip chemotherapy, radiation, and surgery, but the broader pivotal data land short of the famous 100% single-center result.
- Author: Finance Herald Staff
- Tags: Health & Pharma, News

On October 19, the Food and Drug Administration cleared GSK's dostarlimab, sold as Jemperli, as a treatment for adults with locally advanced rectal cancer. The [approval](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-locally-advanced-rectal-cancer?ref=financeherald.com) is limited to patients whose tumors are microsatellite instability-high or mismatch repair deficient, a biomarker profile found in roughly 5-10% of rectal cancers.

For that subset, the decision moves the standard of care. The current path for locally advanced rectal cancer stacks chemotherapy, radiation, and surgery together, a combination GSK [says](https://us.gsk.com/en-us/media/press-releases/jemperli-dostarlimab-gxly-approved-in-us-as-first-and-only-immunotherapy-for-adults-with-msi-hdmmr-locally-advanced-rectal-cancer/?ref=financeherald.com) can leave lasting bowel, urinary, and sexual dysfunction, plus a risk of secondary cancers and infertility. A checkpoint inhibitor that clears tumors on its own would let patients avoid all three interventions and keep their organs.

The evidence behind that promise is real, but more qualified than the story that made the drug famous.

### The 100% result and the broader trial

The viral result came from a small investigator-led [study](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-locally-advanced-rectal-cancer?ref=financeherald.com) the FDA also reviewed: 50 patients on the same regimen posted a 100% objective response rate and a 93% sustained clinical complete response at 12 months, and none received chemoradiation or rectal cancer surgery. The registrational trial that supported the marketing clearance is more modest.

In AZUR-1, a 154-patient, single-arm trial, patients took 500 milligrams of dostarlimab intravenously every three weeks for nine cycles, roughly six months of treatment. By independent central review, 47% of evaluable patients achieved a sustained complete response at 12 months, while investigator assessment put the figure at 68%, with an objective response rate of 82%. Of the 154 treated, 110 (71%) got dostarlimab alone and never progressed, while 26 (17%) still went to surgery and 13 (8%) received further systemic therapy or radiation. Over a median 26.3 months of follow-up, none of the patients who reached a complete response saw their disease return.

### What organ sparing actually buys

The stakes run deeper than convenience. Surgery and radiation for this disease can be permanently altering, which is partly why the prospect of avoiding them carries so much weight. Of the 15 patients who did go to surgery after dostarlimab alone because imaging suggested an incomplete response, 12 turned out to have no cancer left on tissue analysis, a sign some operations removed little more than uncertainty.

Safety ran broadly in line with Jemperli's known profile. Serious adverse reactions occurred in 20% of patients, with fatigue (32%), rash (22%), diarrhea (18%), and pruritus (17%) the most common, and 3% stopped treatment because of side effects.

### A first-mover approval with strings attached

The clearance is explicitly conditional. It came through the FDA's accelerated pathway, and the prescribing information cautions that the long-term risk of relapse is unknown, with continued approval potentially contingent on a confirmatory [trial](https://us.gsk.com/en-us/media/press-releases/jemperli-dostarlimab-gxly-approved-in-us-as-first-and-only-immunotherapy-for-adults-with-msi-hdmmr-locally-advanced-rectal-cancer/?ref=financeherald.com). That caveat matters because organ sparing only works if the responses hold up over years.

For GSK, the decision deepens an immuno-oncology franchise in which Jemperli is already approved in endometrial cancer and other mismatch-repair-deficient solid tumors. The drug was discovered by AnaptysBio and licensed through TESARO, with GSK responsible for its development and commercialization. Tony Wood, GSK's chief scientific officer, framed the milestone as a shift after decades in which treatment "relied on chemotherapy, radiation and surgery." The agency granted the filing priority review and breakthrough-therapy designation, cleared it four months ahead of its goal date, and ran the review through Project Orbis alongside regulators in Canada, Israel, Switzerland, and the United Kingdom.

Whether organ preservation becomes routine hinges on the confirmatory data still maturing. For now, the approval hands a small group of patients a genuine choice to keep their bodies intact, with the honest caveat that the label itself leaves open exactly how long those responses will last.